Key result
Higher circulating CGRP in cirrhosis correlates with lower systemic vascular resistance and central blood volume.
Why the study?
The aetiology of reduced systemic vascular resistance and abnormal vascular filling in cirrhosis remains obscure, with recent reports of increased CGRP concentrations in cirrhosis.
Is circulating calcitonin gene-related peptide (CGRP) associated with systemic vasodilatation and central hypovolaemia in patients with cirrhosis?
Observational (n=37)
Is circulating calcitonin gene-related peptide (CGRP) associated with systemic vasodilatation and central hypovolaemia in patients with cirrhosis?
p-value: p=<0.02
Increased CGRP levels correlate with reduced systemic vascular resistance and central blood volume in cirrhosis, suggesting a mechanistic role in systemic vasodilatation.
CGRP may contribute to vasodilatation in cirrhosis; hypothesis-generating without causal evidence.
BACKGROUND: The aetiology of the reduced systemic vascular resistance and abnormal 'filling' of the vascular bed in cirrhosis is still obscure. As increased concentrations of the potent vasodilator calcitonin gene-related peptide (CGRP) have recently been reported in cirrhosis, we related CGRP to central and peripheral haemodynamics in patients with cirrhosis. METHODS: Thirty-one cirrhotic patients and six control subjects underwent an investigation with determination of systemic haemodynamics and circulating CGRP. RESULTS: Circulating CGRP was significantly increased in patients with cirrhosis (P < 0.02) and covaried directly with the severity of cirrhosis (P < 0.02). The increased CGRP covaried negatively with the reduced systemic vascular resistance (P < 0.02), the reduced central blood volume (P < 0.01), and reduced central circulation time (P < 0.002) and positively with the non-central blood volume (P < 0.05). CONCLUSIONS: These results suggest that increased CGRP may play a role in the systemic vasodilatation in cirrhosis and may contribute to the abnormal distribution of the blood volume, which may lead to abnormal sodium and water handling.
No takes yet. Share an insight, caveat, or question.
Møller et al. (1996) conducted an observational in Cirrhosis (n=37). Circulating calcitonin gene-related peptide (CGRP) vs. Control subjects was evaluated on Systemic haemodynamics and circulating CGRP levels (p=<0.02). Circulating CGRP was significantly increased in patients with cirrhosis (P<0.02) and covaried negatively with systemic vascular resistance (P<0.02) and central blood volume (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: